VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA).
Morning Overview on MSN
New tool automates key steps in genome sequencing analysis
A Snakemake-based pipeline called Pipeasm automates key steps of genome assembly, from raw read trimming through scaffolding and contamination screening, and the authors report up to 99.6% BUSCO ...
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization. HENDERSON, Nev., March 18, ...
Market Outlook and Growth TrajectoryThe global next generation sequencing market is poised to experience robust expansion, registering an estimated growth rate of around 15% over the next five years.
Integrative high-throughput studies identify novel targets and drugs for advanced prostate cancer treatment Prostate cancer, a prevalent malignancy ...
Mass spectrometry is already a powerful tool for determining what kind and how many molecules are present in a given sample. But most instruments still analyze their molecules one or just a few at a ...
Infectious keratitis remains a leading cause of corneal blindness and visual impairment worldwide, with bacterial, fungal, amoebic and viral pathogens presenting major diagnostic and therapeutic ...
Animal Genetics Market OverviewThe Animal Genetics Market is anticipated to grow at a CAGR of 6–7% between 2023 and 2028. This upward trajectory is driven by several influential factors, including the ...
Rivian unveiled the R2 at SXSW today. Here's what it costs, when cheaper trims arrive, and what Wall Street thinks about the company's outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results